Author: ABLi Therapeutics

Posted Date:

May 6, 2026

ABLi Therapeutics Appoints Industry Veteran Dr. Rachelle S. Doody to its Board of Directors

ABLi Therapeutics

May 6, 2026
ABLi Therapeutics to Present at the Citizens Life Sciences Conference

ABLi Therapeutics

March 5, 2026
ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease

ABLi Therapeutics

February 20, 2026
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial

ABLi Therapeutics

January 28, 2026